HIV-associated opportunistic CNS infections: Pathophysiology, diagnosis and treatment

Nature Reviews Neurology

Volumn 12, Issue 11, 2016, Pages 662-674

  Bowen, Lauren N ^a   Smith, Bryan ^a   Reich, Daniel ^a   Quezado, Martha ^b   Nath, Avindra ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CIDOFOVIR; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; CYTARABINE; DEXAMETHASONE; ETHAMBUTOL; FLUCONAZOLE; FLUCYTOSINE; FOLINIC ACID; FOSCARNET; GANCICLOVIR; ISONIAZID; ITRACONAZOLE; MEFLOQUINE; POSACONAZOLE; PYRAZINAMIDE; PYRIMETHAMINE; RIFAMPICIN; SULFADIAZINE; VALGANCICLOVIR; VORICONAZOLE;

ANTIGEN DETECTION; BRAIN ABSCESS; BRAIN BIOPSY; CENTRAL NERVOUS SYSTEM INFECTION; CEREBRAL TOXOPLASMOSIS; CEREBROSPINAL FLUID; CHORIORETINITIS; CRYPTOCOCCAL MENINGITIS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; ENCEPHALITIS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPETENCE; MEDICATION COMPLIANCE; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; POLYRADICULITIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RISK FACTOR; SEROLOGY; TUBERCULOUS MENINGITIS; VIRUS ENCEPHALITIS; AIDS RELATED COMPLEX; COMPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CYTOMEGALOVIRUS INFECTIONS; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MENINGITIS, CRYPTOCOCCAL; TOXOPLASMOSIS, CEREBRAL; TUBERCULOSIS, MENINGEAL;

EID: 84994168881     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2016.149     Document Type: Review

References (115)

1. Wong, A. A., Pabbaraju, K., Wong, S. & Tellier, R. Development of a multiplex real-time PCR for the simultaneous detection of herpes simplex and varicella zoster viruses in cerebrospinal fluid and lesion swab specimens. J. Virol. Methods 229, 16-23 (2016).
2. Garvey, L. et al. HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur. J. Neurol. 18, 527-534 (2011).
3. Lanoy, E. et al. Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology 76, 644-651 (2011).
4. Caniglia, E. C. et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 83, 134-141 (2014).
5. Ferguson, D. J. & Hutchison, W. M. The host-parasite relationship of Toxoplasma gondii in the brains of chronically infected mice. Virchows Arch. A Pathol. Anat. Histopathol. 411, 39-43 (1987).
6. Chew, W. K., Wah, M. J., Ambu, S. & Segarra, I. Toxoplasma gondii: determination of the onset of chronic infection in mice and the in vitro reactivation of brain cysts. Exp. Parasitol. 130, 22-25 (2012).
7. McCabe, R. E., Brooks, R. G., Dorfman, R. F. & Remington, J. S. Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy. Rev. Infect. Dis. 9, 754-774 (1987).
8. Zhang, Y. H. et al. Activated microglia contribute to neuronal apoptosis in toxoplasmic encephalitis. Parasit. Vectors 7, 372 (2014).
9. Luft, B. J. et al. Outbreak of central-nervous-system toxoplasmosis in western Europe and North America. Lancet 1, 781-784 (1983).
10. Coelho, L. et al. Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil. PLoS ONE 9, e98666 (2014).
11. Laing, R. B., Flegg, P. J., Brettle, R. P., Leen, C. L. & Burns, S. M. Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients. Int. J. STD AIDS 7, 258-264 (1996).
12. Jones, J. L., Kruszon-Moran, D., Rivera, H. N., Price, C. & Wilkins, P. P. Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades. Am. J. Trop. Med. Hyg. 90, 1135-1139 (2014).
13. Montoya, J. G. & Liesenfeld, O. Toxoplasmosis. Lancet 363, 1965-1976 (2004).
14. Antinori, A. et al. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin. Infect. Dis. 39, 1681-1691 (2004).
15. Leon Ruiz, M. A. Novel case of solitary cerebral toxoplasmosis mimicking glioblastoma as the first presentation of HIV. J. Clin. Neurol. 12, 248-250 (2016).
16. Nath, A., Hobson, D. E. & Russell, A. Movement disorders with cerebral toxoplasmosis and AIDS. Mov. Disord. 8, 107-112 (1993).
17. Mattos, J. P., Rosso, A. L., Correa, R. B. & Novis, S. A. Movement disorders in 28 HIV-infected patients. Arq. Neuropsiquiatr. 60, 525-530 (2002).
18. Herrera Rubio, J., Farinas, M. C., Tejido, R., Garcia Palomo, J. D. & Tejido, R. [Aspecific chorioretinitis as initial manifestation of HIV infection and diffuse Toxoplasma encephalitis]. Med. Clin. (Barc.) 106, 198-199 (in Spanish) (1996).
19. Gray, F. et al. Diffuse encephalitic cerebral toxoplasmosis in AIDS. Report of four cases. J. Neurol. 236, 273-277 (1989).
20. de?la?Torre, A. et al. Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia. Clin. Exp. Ophthalmol. 37, 458-466 (2009).
21. Rodriguez, A. et al. Referral patterns of uveitis in a tertiary eye care center. Arch. Ophthalmol. 114, 593-599 (1996).
22. Crosson, J. N., Laird, P. W., Grossniklaus, H. E. & Hendrick, A. M. Toxoplasma chorioretinitis diagnosed by histopathology in a patient with AIDS. Retin. Cases Brief Rep. 9, 162-163 (2015).
23. Cochereau-Massin, I. et al. Ocular toxoplasmosis in human immunodeficiency virus-infected patients. Am. J. Ophthalmol. 114, 130-135 (1992).
24. Furtado, J. M., Toscano, M., Castro, V. & Rodrigues, M. W. Roth spots in ocular toxoplasmosis. Ocul. Immunol. Inflamm. http://dx.doi.org/10.3109/09273948.2015.1047035 (2015).
25. Gagliuso, D. J., Teich, S. A., Friedman, A. H. & Orellana, J. Ocular toxoplasmosis in AIDS patients. Trans. Am. Ophthalmol. Soc. 88, 63-86 (1990).
26. Belaz, S., Gangneux, J. P., Dupretz, P., Guiguen, C. & Robert-Gangneux, F. A. 10?year retrospective comparison of two target sequences, REP?529 and B1, for Toxoplasma gondii detection by quantitative PCR. J. Clin. Microbiol. 53, 1294-1300 (2015).
27. Colombo, F. A. et al. Diagnosis of cerebral toxoplasmosis in AIDS patients in Brazil: importance of molecular and immunological methods using peripheral blood samples. J. Clin. Microbiol. 43, 5044-5047 (2005).
28. Meira, C. S. et al. IgG4 specific to Toxoplasma gondii excretory/secretory antigens in serum and/or cerebrospinal fluid support the cerebral toxoplasmosis diagnosis in HIV-infected patients. J. Immunol. Methods 395, 21-28 (2013).
29. Marra, C. M., Krone, M. R., Koutsky, L. A. & Holmes, K. K. Diagnostic accuracy of HIV-associated central nervous system toxoplasmosis. Int. J. STD AIDS 9, 761-764 (1998).
30. Mathews, C., Barba, D. & Fullerton, S. C. Early biopsy versus empiric treatment with delayed biopsy of nonresponders in suspected HIV-associated cerebral toxoplasmosis: a decision analysis. AIDS 9, 1243-1250 (1995).
31. Neville, A. J. et al. Clinically available medicines demonstrating anti-toxoplasma activity. Antimicrob. Agents Chemother. 59, 7161-7169 (2015).
32. Vidadala, R. S. et al. Development of an orally available and central nervous system (CNS) penetrant Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitor with minimal human ether?a?go?go?related gene (hERG) activity for the treatment of toxoplasmosis. J. Med. Chem. 59, 6531-6546 (2016).
33. Gorelik, L. et al. Anti?JC virus antibodies: implications for PML risk stratification. Ann. Neurol. 68, 295-303 (2010).
34. Engsig, F. N. et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J. Infect. Dis. 199, 77-83 (2009).
35. Fong, I. W. & Toma, E. The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Canadian PML Study Group. Clin. Infect. Dis. 20, 1305-1310 (1995).
36. Worthley, D. L., Sandhu, A. & Norton, G. Progressive multifocal leukoencephalopathy: a confused woman, an ambitious virus and an unusual MRI. Intern. Med. J. 32, 266-267 (2002).
37. Saito, H., Sakai, H., Fujihara, K., Fujihara, K. & Itoyama, Y. Progressive multifocal leukoencephalopathy in a patient with acquired immunodeficiency syndrome (AIDS) manifesting Gerstmann's syndrome. Tohoku J. Exp. Med. 186, 169-179 (1998).
38. Willott, R. H., Sunman, W. & Munshi, S. K. Progressive multifocal leukoencephalopathy masquerading as cerebellar infarction. Age Ageing 45, 564-565 (2016).
39. Stockhammer, G. et al. Progressive multifocal leukoencephalopathy presenting with an isolated focal movement disorder. Mov. Disord. 15, 1006-1009 (2000).
40. Jeyaraman, V. A. et al. Isolated cortical blindness without simultaneous neurological involvement in progressive multifocal leukoencephalopathy in a patient with human immune deficiency virus infection. J. Ophthalmic Inflamm. Infect. 3, 3 (2013).
41. Boster, A. L. et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol. 70, 398-402 (2013).
42. Koralnik, I. J. et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann. Neurol. 57, 576-580 (2005).
43. Casado, J. L. et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur. J. Clin. Microbiol. Infect. Dis. 33, 179-187 (2014).
44. Khanna, N. et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin. Infect. Dis. 48, 1459-1466 (2009).
45. Tan, K., Roda, R., Ostrow, L., McArthur, J. & Nath, A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72, 1458-1464 (2009).
46. Clifford, D. B. et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9, 438-446 (2010).
47. Berger, J. R. et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80, 1430-1438 (2013).
48. Kuker, W. et al. Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrast-enhanced magnetic resonance imaging for diagnosis and treatment control. Eur. J. Neurol. 13, 819-826 (2006).
49. Astrom, K. E., Mancall, E. L. & Richardson, E. P. Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81, 93-111 (1958).
50. Marra, C. M. et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 16, 1791-1797 (2002).
51. Aksamit, A. J. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J. Neurovirol. 7, 386-390 (2001).
52. Clifford, D. B. et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J. Neurovirol. 19, 351-358 (2013).
53. Cettomai, D. & McArthur, J. C. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch. Neurol. 66, 255-258 (2009).
54. Blumberg, H. M. et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603-662 (2003).
55. Kwan, C. K. & Ernst, J. D. HIV and tuberculosis: a deadly human syndemic. Clin. Microbiol. Rev. 24, 351-376 (2011).
56. Jarvis, J. N. et al. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect. Dis. 10, 67 (2010).
57. Simmons, C. P. et al. Pretreatment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous meningitis: diagnostic value and relationship to disease severity and outcome. J. Immunol. 176, 2007-2014 (2006).
58. Marais, S., Pepper, D. J., Marais, B. J. & Torok, M. E. HIV-associated tuberculous meningitis-diagnostic and therapeutic challenges. Tuberculosis (Edinb.) 90, 367-374 (2010).
59. Marais, S. et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect. Dis. 10, 803-812 (2010).
60. Thwaites, G. E. et al. Comparison of conventional bacteriology with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculosis chemotherapy. J. Clin. Microbiol. 42, 996-1002 (2004).
61. Raja, S. et al. Technology for automated, rapid, and quantitative PCR or reverse transcription-PCR clinical testing. Clin. Chem. 51, 882-890 (2005).
62. Boehme, C. C. et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363, 1005-1015 (2010).
63. Zignol, M. et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull. World Health Organ. 90, 111-119D (2012).
64. World Health Organization. Multidrug-resistant tuberculosis (MDR?TB): 2013 Update. http://www.who. int/tb/challenges/mdr/MDR-TB-FactSheet.pdf (2013).
65. Syed Ahamed Kabeer, B. et al. Role of interferon ? release assay in active TB diagnosis among HIV infected individuals. PLoS ONE 4, e5718 (2009).
66. Kaur, H. et al. Prospective analysis of 55 cases of tuberculosis meningitis (TBM) in North India. J. Clin. Diagn. Res. 19, DC15-DC19 (2015).
67. Singh, A. K. et al. Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis. BMC Infect. Dis. 16, 306 (2016).
68. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIVinfected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. AIDSinfo. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult-oi.pdf (accessed July 31 2016).
69. Regazzi, M., Carvalho, A. C., Villani, P. & Matteelli, A. Treatment optimization in patients co?infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin. Pharmacokinet. 53, 489-507 (2014).
70. Luetkemeyer, A. F. Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States. Top. HIV Med. 18, 143-148 (2010).
71. Thwaites, G. E. et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351, 1741-1751 (2004).
72. Torok, M. E. et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin. Infect. Dis. 52, 1374-1383 (2011).
73. Daikos, G. L., Cleary, T., Rodriguez, A. & Fischl, M. A. Multidrug-resistant tuberculous meningitis in patients with AIDS. Int. J. Tuber. Lung Dis. 7, 394-398 (2003).
74. Patel, V. B. et al. Multidrug-resistant tuberculous meningitis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 38, 851-856 (2004).
75. Dodt, K. K. et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS 11, F21-F28 (1997).
76. Rhein, J. et al. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect. Dis. 16, 809-818 (2016).
77. Albarillo, F. & O'Keefe, P. Opportunistic neurologic infections in patients with acquired immunodeficiency syndrome (AIDS). Curr. Neurol. Neurosci. Rep. 16, 10 (2016).
78. Jarvis, J. N. et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. Clin. Infect. Dis. 58, 736-745 (2014).
79. Jarvis, J. N. et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin. Infect. Dis. 48, 856-862 (2009).
80. French, N. et al. Cryptococcal infection in a cohort of HIV?1?infected Ugandan adults. AIDS 16, 1031-1038 (2002).
81. Liechty, C. A. et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop. Med. Int. Health 12, 929-935 (2007).
82. Mfinanga, S. et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet 385, 2173-2182 (2015).
83. Hardison, S. E. et al. Pulmonary infection with an interferon-?-producing Cryptococcus neoformans strain results in classical macrophage activation and protection. Am. J. Pathol. 176, 774-785 (2010).
84. Boulware, D. R. et al. Human immune response varies by the degree of relative cryptococcal antigen shedding. Open Forum Infect. Dis. 3, ofv194 (2016).
85. Tan, I. L., Smith, B. R., von Geldern, G., Mateen, F. J. & McArthur, J. C. HIV-associated opportunistic infections of the CNS. Lancet Neurol. 11, 605-617 (2012).
86. Kammalac Ngouana, T. et al. Cryptoccocal meningitis in Yaounde (Cameroon) HIV infected patients: diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole. J. Mycol. Med. 25, 11-16 (2015).
87. Boulware, D. R. et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg. Infect. Dis. 20, 45-53 (2014).
88. Troncoso, A. et al. CNS cryptococcoma in an HIVpositive patient. J. Int. Assoc. Physicians AIDS Care (Chic.) 1, 131-133 (2002).
89. Charlier, C. et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS ONE 3, e1950 (2008).
90. Loyse, A. et al. Neurological, visual, and MRI brain scan findings in 87 South African patients with HIVassociated cryptococcal meningoencephalitis. J. Infect. 70, 668-675 (2015).
91. Katchanov, J. et al. Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution. Int. J. STD AIDS 26, 912-914 (2015).
92. Offiah, C. E. & Naseer, A. Spectrum of imaging appearances of intracranial cryptococcal infection in HIV/AIDS patients in the anti-retroviral therapy era. Clin. Radiol. 71, 9-17 (2016).
93. Cherian, J., Atmar, R. L. & Gopinath, S. P. Shunting in cryptococcal meningitis. J. Neurosurgery 125, 177-186 (2016).
94. Chen, C. H. et al. Epidemiological characterization and prognostic factors in patients with confirmed cerebral cryptococcosis in central Taiwan. J. Venom. Anim. Toxins Incl. Trop. Dis. 21, 12 (2015).
95. Rolfes, M. A. et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin. Infect. Dis. 59, 1607-1614 (2014).
96. Boulware, D. R. et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 7, e1000384 (2010).
97. Boulware, D. R. et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J. Infect. Dis. 202, 962-970 (2010).
98. Boulware, D. R. et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N. Engl. J. Med. 370, 2487-2498 (2014).
99. Day, J. N. et al. Combination antifungal therapy for cryptococcal meningitis. N. Engl. J. Med. 368, 1291-1302 (2013).
100. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIVinfected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.Cytomegalovirus disease (N-1). AIDSinfo. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult-oi.pdf. (accessed August 4 2016).
101. Saag, M. S. et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDSassociated cryptococcal meningitis. Clin. Infect. Dis. 28, 291-296 (1999).
102. Yao, Y. et al. Voriconazole: a novel treatment option for cryptococcal meningitis. Infect. Dis. (Lond.) 47, 694-700 (2015).
103. Warrilow, A. G. et al. The investigational drug VT?1129 is a highly potent inhibitor of cryptococcus species CYP51 but only weakly inhibits the human enzyme. Antimicrob. Agents Chemother. 60, 4530-4538 (2016).
104. Beardsley, J. et al. Adjunctive dexamethasone in HIVassociated cryptococcal meningitis. N. Engl. J. Med. 374, 542-554 (2016).
105. Anduze-Faris, B. M. et al. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. AIDS 14, 517-524 (2000).
106. Silva, C. A. et al. Neurologic cytomegalovirus complications in patients with AIDS: retrospective review of 13 cases and review of the literature. Rev. Inst. Med. Trop. Sao Paulo 52, 305-310 (2010).
107. Kuo, I. C., Kempen, J. H., Dunn, J. P., Vogelsang, G. & Jabs, D. A. Clinical characteristics and outcomes of cytomegalovirus retinitis in persons without human immunodeficiency virus infection. Am. J. Ophthalmol. 138, 338-346 (2004).
108. Jabs, D. A. et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1 Retinitis progression. Ophthalmology 111, 2224-2231 (2004).
109. Mofenson, L. M. et al. Guidelines for the prevention and treatment of opportunistic infections among HIVexposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR. Recommendations and reports: morbidity and mortality weekly report. MMWR Recomm. Rep. 58, 1-166 (2009).
110. Martin, D. F. et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med. 346, 1119-1126 (2002).
111. Jabs, D. A., Ahuja, A., Van Natta, M., Dunn, J. P. & Yeh, S. Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 120, 1262-1270 (2013).
112. Morrison, V. L. et al. Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology 114, 334-339 (2007).
113. Alvarez-Uria, G., Naik, P. K., Pakam, R., Bachu, L. & Midde, M. Natural history and factors associated with early and delayed mortality in HIV-infected patients treated of tuberculosis under directly observed treatment short-course strategy: a prospective cohort study in India. Interdiscip. Perspect. Infect. Dis. 2012, 502012 (2012).
114. Luma, H. N. et al. Tuberculous meningitis: presentation, diagnosis and outcome in hiv-infected patients at the douala general hospital, cameroon: a cross sectional study. AIDS Res. Ther. 10, 16 (2013).
115. Xiao, J. et al. Spectrums of opportunistic infections and malignancies in HIV-infected patients in tertiary care hospital, China. PLoS ONE 8, e75915 (2013).